These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7998103)

  • 1. ATG in steroid-resistant acute rejection in living related kidney transplantation: long-term evaluation.
    Bakr MA; Foda MA; Sally S; Sobh MA; Ghoneim MA
    Transplant Proc; 1994 Dec; 26(6):3161-2. PubMed ID: 7998103
    [No Abstract]   [Full Text] [Related]  

  • 2. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
    Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
    Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
    [No Abstract]   [Full Text] [Related]  

  • 3. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 4. Kidney transplantation in Cyprus.
    Kyriakides GK; Hadjigavriel M; Nicolaou P; Nicolaides A; Kyriakides M
    Transplant Proc; 1993 Apr; 25(2):2129-30. PubMed ID: 8470291
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of cyclosporine rescue therapy in steroid resistant rejections.
    Sharma RK; Elhence R; Kher V; Gupta A; Kumar A; Bhandari M; Agrawal S
    Transplant Proc; 1994 Oct; 26(5):2556-7. PubMed ID: 7940789
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclosporin monotherapy in pancreaticorenal transplantation.
    Ward RG; Gecim E; Bone JM; Bakran A; Sells RA
    Transplant Proc; 1994 Apr; 26(2):548. PubMed ID: 8171547
    [No Abstract]   [Full Text] [Related]  

  • 7. Three-day or ten-day ATG treatment for steroid-resistant rejection in kidney transplanted patients.
    Olausson M; Mjörnstedt L; Blohmé I
    Transplant Proc; 1995 Dec; 27(6):3434-5. PubMed ID: 8540037
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 9. OKT3 for steroid-resistant renal allograft rejection: differential response in adults and children.
    Shmueli D; Nakache R; Lustig S; Bar Nathan N; Yussim A; Shaharabani E; Geier A; Shapira Z
    Transplant Proc; 1994 Aug; 26(4):1948-9. PubMed ID: 8066630
    [No Abstract]   [Full Text] [Related]  

  • 10. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
    Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
    Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcome of live-related donor renal transplants in their second decade.
    Georgi BA; Cacciarelli TV; Sumrani N; Goldberg K; Hong JH; Sommer BG
    Transplant Proc; 1993 Jun; 25(3):2164-5. PubMed ID: 8516853
    [No Abstract]   [Full Text] [Related]  

  • 12. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
    Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
    Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of cyclosporine monotherapy--long-term graft function.
    Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
    Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of donor age and acute rejection episodes on long-term graft survival in cadaveric kidney transplantations.
    Emiroğlu R; Yagmurdur MC; Karakayali F; Haberal C; Ozcelik U; Colak T; Haberal M
    Transplant Proc; 2005 Sep; 37(7):2954-6. PubMed ID: 16213272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and renal histologic predictors of long-term outcome after OKT3 therapy for steroid-resistant rejection.
    Wiener Y; Nakhleh RE; Kupin WL; Lee M; Escobar FS; Venkat KK; Mozes MF
    Transplant Proc; 1995 Feb; 27(1):1014-5. PubMed ID: 7878781
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute rejection after living donor renal transplantation.
    Cho WH; Park CH; Lee SH; Park SB; Kim HC
    Transplant Proc; 1994 Aug; 26(4):1995-6. PubMed ID: 8066647
    [No Abstract]   [Full Text] [Related]  

  • 17. Antilymphoblast globulin treatment of steroid-resistant rejection in cyclosporine-immunosuppressed renal transplant recipients.
    Tellis VA; Matas AJ; Quinn TA; Glicklich D; Weiss RJ; Soberman RJ; Veith FJ
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1892. PubMed ID: 3274447
    [No Abstract]   [Full Text] [Related]  

  • 18. Update of our experience in long-term renal function of kidneys transplanted from non-heart-beating cadaver donors.
    Castelao AM; Griñó JM; González C; Franco E; GilVernet S; Andrés E; Serón D; Torras J; Moreso F; Alsina J
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1513-5. PubMed ID: 8442170
    [No Abstract]   [Full Text] [Related]  

  • 19. Donor-specific transfusion in living-related renal transplants.
    Basri N; Nezamuddin N; Aman H; Banqash H; Sharwani N
    Transplant Proc; 1992 Oct; 24(5):1746. PubMed ID: 1412822
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts.
    Broyer M; Gagnadoux MF; Guest G; Arsan A; Beurton D; Revillon Y; Niaudet P
    Transplant Proc; 1993 Feb; 25(1 Pt 1):570-1. PubMed ID: 8438418
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.